KR102534513B1 - Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same - Google Patents
Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same Download PDFInfo
- Publication number
- KR102534513B1 KR102534513B1 KR1020200128712A KR20200128712A KR102534513B1 KR 102534513 B1 KR102534513 B1 KR 102534513B1 KR 1020200128712 A KR1020200128712 A KR 1020200128712A KR 20200128712 A KR20200128712 A KR 20200128712A KR 102534513 B1 KR102534513 B1 KR 102534513B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- antioxidant
- immunity
- immune
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 42
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 32
- 235000013376 functional food Nutrition 0.000 title claims abstract description 23
- 230000036541 health Effects 0.000 title claims abstract description 22
- 230000036039 immunity Effects 0.000 title claims description 33
- 230000000694 effects Effects 0.000 title abstract description 28
- 241000364150 Callophyllis rhynchocarpa Species 0.000 title description 2
- 240000000275 Persicaria hydropiper Species 0.000 claims abstract description 21
- 235000017337 Persicaria hydropiper Nutrition 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 7
- 241000243681 Eisenia bicyclis Species 0.000 claims description 6
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 5
- 235000020721 horse chestnut extract Nutrition 0.000 claims description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 210000003323 beak Anatomy 0.000 abstract description 14
- 239000000796 flavoring agent Substances 0.000 abstract description 11
- 235000019634 flavors Nutrition 0.000 abstract description 8
- 235000019629 palatability Nutrition 0.000 abstract description 8
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 239000005445 natural material Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 23
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 19
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 19
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 240000007594 Oryza sativa Species 0.000 description 10
- 235000007164 Oryza sativa Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000009566 rice Nutrition 0.000 description 10
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000015788 innate immune response Effects 0.000 description 7
- 235000013379 molasses Nutrition 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000005965 immune activity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000020991 processed meat Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000004263 Guaiac resin Substances 0.000 description 1
- 229920000932 Gum guaicum Polymers 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229940070404 citrus bioflavonoids Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 235000019278 guaiac resin Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 101800000857 p40 protein Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 235000019511 tuna Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 부리붉은잎을 포함하는 기능성 조성물 및 이를 포함하는 건강기능식품에 관한 것이다. 본 발명에 따른 항산화 및 면역력 개선용 조성물은 부리붉은잎 추출물을 포함하는 것이다.
상기 조성물에 의하는 경우 항산화 및 면역력 개선 활성을 높이면서도 천연물 기반의 소재로서, 부작용의 문제없이 장기간 복용할 수 있고, 향미와 기호성이 우수할 수 있다.The present invention relates to a functional composition containing red beak leaves and a health functional food containing the same. Antioxidant and immune-improving composition according to the present invention is to include a beak red leaf extract.
In the case of using the composition, as a natural material-based material while enhancing antioxidant and immunity-improving activities, it can be taken for a long period of time without side effects and has excellent flavor and palatability.
Description
본 발명은 부리붉은잎 추출물을 포함하는 항산화 및 면역력 개선용 조성물 및 이를 포함하는 건강기능식품에 관한 것이다. 보다 상세하게는 부리붉은잎 추출물 또는 발효된 부리붉은잎 추출물을 유효성분으로 포함하면서, 항산화 및 면역력 개선효과를 나타내는 기능성 조성물과 이를 포함하는 건강기능식품을 제공하기 위한 것이다.The present invention relates to a composition for antioxidation and immunity improvement containing a red leaf extract and a health functional food containing the same. More specifically, it is to provide a functional composition showing antioxidant and immune-improving effects and a health functional food containing the same, while containing the fermented red leaf extract or fermented red leaf extract as an active ingredient.
인체에서 산소를 소비하는 과정으로 인해 불가피하게 발생하는 부산물인 과산화수소(hydrogen peroxide, H2O2), 초과산화음이온(superoxide anion, O2 -), 하이드록실라디칼(hydroxyl radical, OH) 등과 같은 활성 산소종(reactive oxygen species; ROS)은 생체 내에서의 높은 반응성으로 인하여 독성을 유발한다. 적정량의 활성 산소종은 생체 내에서 세포내 신호전달 물질로 작용함으로써, 미토콘드리아 내의 전자전달계 및 백혈구 세포의 활성화 등 세포기능을 유지하는데 중요한 역할을 담당한다. 반면, 과잉 생성된 활성 산소종은 생체 내의 산화방지균형을 무너뜨림으로써 산화적 스트레스를 야기한다. 활성산소의 독성이 세포 구성성분들인 지방질, 단백질, 당 및 DNA 등을 비선택적, 비가역적으로 손상시켜 암을 비롯하여 뇌졸중, 알츠하이머병 등과 같은 뇌질환과 심장질환, 동맥경화, 염증 및 자가면역질환 등의 각종 질병 및 조화를 일으킬 수 있다.Activities such as hydrogen peroxide (H 2 O 2 ), superoxide anion (O 2 - ), and hydroxyl radical (OH), which are inevitable by-products caused by the process of consuming oxygen in the human body Oxygen species (reactive oxygen species; ROS) cause toxicity due to their high reactivity in vivo. An appropriate amount of reactive oxygen species plays an important role in maintaining cellular functions such as electron transport system in mitochondria and activation of white blood cells by acting as intracellular signaling substances in vivo. On the other hand, excessively produced reactive oxygen species cause oxidative stress by breaking the antioxidant balance in the body. The toxicity of reactive oxygen species damages cell components such as lipids, proteins, sugars, and DNA non-selectively and irreversibly, resulting in cancer, brain diseases such as stroke and Alzheimer's disease, heart disease, arteriosclerosis, inflammation, and autoimmune diseases. can cause various diseases and harmonization of
생체 내에서 카탈레이스(catalase, CAT), 글루타싸이온과산화효소(glutathione peroxidase, GSH-Px), 초과산화물제거효소(superoxidedismutase, SOD)와 같은 내인성 산화방지효소들은 활성산소와의 균형을 유지함으로써 DNA 손상, 단백질 변형 및 지방질 과산화를 예방한다. 인간의 신체 부위 중 뇌는 상대적으로 활성산소를 제거하는 내인성 산화방지효소가 적으며, 전체 산소 소비량의 20%를 차지하기 때문에 체내에서 가장 많은 활성산소가 발생하는 부위이다. 또한 뇌는 신경전달 기능으로 인하여 활성 산소종에 의해서 쉽게 산화되는 불포화지방 함량이 높아 다른 장기들에 비해 산화적 스트레스에 매우 취약하므로 과량의 활성 산소종은 신경세포의 사멸을 통한 뇌손상을 일으키게 된다. 이에 따라 산화방지 활성을 통해 활성 산소로 유발된 산화스트레스로부터 신경세포를 보호할 수 있으며, 신경퇴행성질환 예방에 기여한다고 보고되고 있는 페놀성 화합물이 풍부한 천연소재에 대한 관심이 높아지고 있다.Endogenous antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) maintain a balance with active oxygen in vivo. Prevents DNA damage, protein modification and lipid peroxidation. Among human body parts, the brain has relatively few endogenous antioxidant enzymes that remove free radicals, and accounts for 20% of the total oxygen consumption, so it is the part where the largest amount of active oxygen is generated in the body. In addition, the brain has a high content of unsaturated fats that are easily oxidized by reactive oxygen species due to its neurotransmission function, so it is very vulnerable to oxidative stress compared to other organs. Excessive reactive oxygen species causes brain damage through the death of nerve cells. . Accordingly, interest in natural materials rich in phenolic compounds, which are reported to protect nerve cells from oxidative stress induced by active oxygen through antioxidant activity and contribute to the prevention of neurodegenerative diseases, is increasing.
최근 유리 라디컬 소거(free radical scavenger) 역할을 하는 것 중에서 여러 가지 천연물 성분의 개발에 대한 연구가 시도되고 있다. 이러한 연구의 결과, 현재 가장 주목받고 있는 성분들은 식물영양소인 피토뉴트리언트(Phytonutrients)로서, 세계적으로 수많은 논문이 발표되고 있는데, 자몽, 오렌지, 레몬, 탄제린 등에서 추출한 시트러스 바이오플라보노이드(citrus bioflavonoid)와 소나무 껍질과 포도씨에서 추출한 피크노제놀(pycnogenol)이라 불리는 성분 등이 보고되어 있다. 상기 성분 외에도 토코페롤, 아스코르빈산과 그 유도체들, 카로티노이드, 플라보노이드계 화합물들, 인지질, 갈색화 반응생성물, 아미노산, 펩티드, 단백질들, 향신료 추출물 등이 있다.Recently, research on the development of various natural components that act as free radical scavengers has been attempted. As a result of these studies, the ingredients that are currently attracting the most attention are phytonutrients, which are plant nutrients, and numerous papers have been published worldwide. Citrus bioflavonoids and A component called pycnogenol extracted from pine bark and grape seeds has been reported. In addition to the above components, there are tocopherol, ascorbic acid and its derivatives, carotenoids, flavonoid compounds, phospholipids, browning reaction products, amino acids, peptides, proteins, spice extracts, and the like.
한편, 향신료 추출물에 관한 연구는 1940 년대부터 시작된 이래로 최근 관심이 높아지고 있는 분야로서, 특히 로즈마리, 세이지 추출물은 FDA로부터 승인을 받았다. 항신료 추출물로는 상기 성분 외에도 육두구, 정향, 고추 등 많은 성분들이 알려져 있는데, 종류에 따라 정도의 차이는 있으나 유리 래디컬 소거(free radical scavenger)효능을 인정받고 있으며, 기타, 쌀겨에 함유된 오리자놀과 함께 구아이약 수지, 참기름에 들어있는 세시물, 세사몰린, 세사민 등이 많이 알려져 있고 봉선화추출물, 루틴, 소목을 포함한 각종 한약재나 식용식물에서도 이러한 효능이 있다고 보고되고 있다.On the other hand, research on spice extracts has recently been a field of increasing interest since it began in the 1940s, and in particular, rosemary and sage extracts have been approved by the FDA. In addition to the above ingredients, many ingredients such as nutmeg, cloves, and red pepper are known as antiseptic extracts. Although the degree varies depending on the type, the free radical scavenger effect is recognized. In addition, oryzanol and Together, guaiac resin, seshimul, sesamolin, and sesamin in sesame oil are well known, and various herbal medicines and edible plants including balsam extract, rutin, and somok are reported to have this effect.
한편, 면역(Immune)이란 인간 및 동물의 체내에서 외래성 및 내인성 이물질을 생리적으로 인식하여 배제하고, 항상성을 유지하기 위한 기작을 일컫는다. 면역은 크게 두 가지로 분류할 수 있는데, 태어날 때부터 지니고 있는 선천면역(innate immunity)과 후천적으로 생활 등에 적응되어 얻어지는 획득면역(acquired immunity)으로 구분된다.On the other hand, immunity (Immune) refers to a mechanism for physiologically recognizing and excluding exogenous and endogenous foreign substances in the body of humans and animals, and maintaining homeostasis. Immunity can be largely classified into two types, which are divided into innate immunity, which is present from birth, and acquired immunity, which is obtained through adaptation to life.
선천면역은 자연면역이라고도 한다. 항원에 대해 비특이적으로 반응하며 특별한 기억작용은 없다. 선천적인 면역체계로는 항원의 침입을 차단하는 피부·점액조직, 상산성의 위산, 혈액에 존재하는 보체(complement) 등이 있다. 세포로는 식균작용을 담당하는 대식세포(macrophage)와 다형핵백혈구(polymorphonuclear leukocyte), 감염세포를 죽일 수 있는 K세포 등이 있다. 실제로 대부분의 감염은 이 선천면역에 의해 방어된다.Congenital immunity is also called innate immunity. It reacts non-specifically to the antigen and has no special memory function. The innate immune system includes skin and mucous tissues that block the invasion of antigens, acidic gastric acid, and complement present in the blood. Cells include macrophages responsible for phagocytosis, polymorphonuclear leukocytes, and K cells that can kill infected cells. In fact, most infections are defended by this innate immunity.
획득면역은 후천면역이라고도 한다. 처음 침입한 항원에 대해 기억할 수 있고 다시 침입할 때 특이적으로 반응하여 효과적으로 항원을 제거할 수 있다. 선천면역을 보강하는 역할을 한다.Acquired immunity is also called acquired immunity. It can remember the first invaded antigen, and when it invades again, it can specifically react and effectively remove the antigen. It plays a role in reinforcing the innate immunity.
획득면역에는 T세포와 B세포가 있다. 가슴샘의 상피세포에서 특수한 내부 환경과 흉선의 액성인자에 의해 림프구로 분화하는 세포를 T세포라 하며, 가슴샘과 독립되어 골수에서 림프구로 분화하는 세포를 B세포라 한다.Acquired immunity includes T cells and B cells. Cells that differentiate into lymphocytes in the epithelial cells of the thymus gland by the special internal environment and thymic humoral factors are called T cells, and cells that differentiate into lymphocytes in the bone marrow independently of the thymus gland are called B cells.
T세포의 역할은 B세포에 항체생산 자극을 주고 종양 세포 등의 항원을 직접 공격하는 것이며, B세포의 역할은 항원자극 및 T세포를 매개로 한 자극에 따라 항체생산세포로 성숙하여 IgM, IgG, IgA, IgE의 항체를 생산하고 분비하는 것이다.The role of T cells is to stimulate B cells to produce antibodies and directly attack antigens, such as tumor cells. , to produce and secrete antibodies of IgA and IgE.
'건강'은 신체에 이상이 없는 상태, 즉 질병이나 부상이 없는 상태를 뜻한다. 면역력이 높으면 평소에 질병에 잘 걸리지 않으며, 설혹 질병에 걸리더라도 회복이 빠르다. 이러한 건강한 상태를 지속적으로 유지하며 나이를 먹으면 수명이 연장되는 것은 자명한 일이다. 따라서 면역력은 인간의 건강과 수명에 직결되어 있으며, 건강을 유지하고 수명을 연장하기 위해서는 면역력을 관리하는 것이 필수적이라고 할 수 있겠다. 그러나 현대인의 생활 습관을 살펴보면, 스트레스, 운동 부족, 불규칙한 생활 리듬, 균형 잡히지 못한 식생활, 흡연 등 면역력이 저하될 요인이 다수를 차지한다. 환경에는 각종 공해가 만연해 있어 역시 면역력이 저하될 요인이 많다. 따라서 현대인은 면역력 증강을 위해 노력하여야 한다.'Health' refers to a state in which there is no abnormality in the body, that is, a state in which there is no disease or injury. If your immunity is high, you are less likely to get sick, and even if you get sick, you will recover quickly. It is obvious that maintaining such a healthy state continuously and extending lifespan as one ages. Therefore, immunity is directly related to human health and lifespan, and it can be said that it is essential to manage immunity in order to maintain health and extend lifespan. However, looking at the lifestyles of modern people, many factors that decrease immunity, such as stress, lack of exercise, irregular life rhythm, unbalanced diet, and smoking, account for a large number of factors. There are various pollutions in the environment, and there are many factors that can lower immunity. Therefore, modern people should make efforts to enhance immunity.
면역력을 증강하는 방법으로 치모둘린, 브롱코박솜 등의 면역증진제 복용이 있다. 면역증진제는 송아지의 가슴샘 또는 정제된 세균체를 함유한다. 정제된 세균체가 함유된 면역증진제의 체내 작용 기작은 약화된 균을 체내에 투여하여 면역계를 훈련시키는 것이며, 송아지의 가슴샘이 함유된 면역증진제의 체내 작용 기작은 송아지의 가슴샘을 섭취함으로써 T세포를 보충하는 것이다. 그러나 면역증강제는 효과가 매우 미미하며, 식욕이 감소하는 등의 부작용이 있는 실정이다.Immunity boosters such as zimodulin and broncobaxom can be used to boost immunity. Immunostimulants contain bovine thymus glands or purified bacterial bodies. The mechanism of action in the body of the immune enhancer containing purified bacteria is to train the immune system by injecting weakened bacteria into the body. is to do However, the effect of the immune enhancer is very insignificant, and there are side effects such as a decrease in appetite.
이에 따라 본 발명자들은 부작용의 문제없이 장기간 복용할 수 있는 천연물을 기반으로 다양한 소재를 기반으로, 항산화 활성과 함께 면역 개선 활성을 나타낼 수 있는 소재에 대한 연구를 지속하였고, 그 결과 본 발명을 완성하였다.Accordingly, the inventors of the present invention continued research on materials that can exhibit antioxidant activity and immune-improving activity based on various materials based on natural products that can be taken for a long time without side effects, and as a result, the present invention was completed. .
본 발명의 목적은 부리붉은잎 추출물 또는 발효된 부리붉은잎 추출물을 유효성분으로 하면서 세포독성 등의 부작용의 문제가 없으면서도 장기간 복용할 수 있는 기능성 조성물을 제공하기 위한 것이다.An object of the present invention is to provide a functional composition that can be taken for a long period of time without side effects such as cytotoxicity while using the fermented red leaf extract or fermented red leaf extract as an active ingredient.
본 발명의 목적은 항산화 및 면역력 개선효과를 나타낼 수 있는 기능성 조성물을 제공하기 위한 것이다.An object of the present invention is to provide a functional composition capable of exhibiting antioxidant and immune-improving effects.
본 발명의 목적은 향미와 기호성이 우수하여 대중화가 용이한 부리붉은잎 기반의 기능성 식품 또는 건강기능식품을 제공하기 위한 것이다.An object of the present invention is to provide a red leaf-based functional food or health functional food that is easy to popularize due to its excellent flavor and palatability.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 항산화 및 면역력 개선용 조성물은 부리붉은잎 추출물을 포함하는 것일 수 있다.In order to achieve the above object, the composition for improving antioxidant and immunity according to an embodiment of the present invention may include a red beak leaf extract.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 발효된 것일 수 있다.In the composition for improving antioxidant and immunity, the extract may be fermented.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 락토바실러스 카제이(Lactobacillus casei); 락토바실러스 람노수스(Lactobacillus rhamnosus); 비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스균; 비피도 박테리움 브레브(Bifidobacterium breve) 비피더스균; 락토바실러스 아시도 필루스(Lactobacillus acidophilus); 바실러스 서브틸리스(Bacillus subtilis) 및 이들의 혼합물로 이루어진 군에서 선택되는 어느 하나가 접종되어 발효된 것일 수 있다.In the antioxidant and immune-improving composition, the extract is Lactobacillus casei; Lactobacillus rhamnosus; Bifidobacterium bifidum Bifidobacteria; Bifidobacterium breve Bifidobacteria; Lactobacillus acidophilus; Any one selected from the group consisting of Bacillus subtilis and mixtures thereof may be inoculated and fermented.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 물, 탄소수 1 내지 6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 어느 하나를 추출 용매로 하여 추출된 것일 수 있다.In the antioxidant and immunity-improving composition, the extract may be extracted by using any one selected from the group consisting of water, lower alcohols having 1 to 6 carbon atoms, and mixtures thereof as an extraction solvent.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 세모가사리 추출물, 대황(Eisenia bicyclis) 추출물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 더 포함하는 것일 수 있다.In the antioxidant and immunity-improving composition, the extract may further include any one selected from the group consisting of semogasari extract, rhubarb (Eisenia bicyclis) extract, and mixtures thereof.
본 발명의 다른 일 실시예에 따른 식품은 상기 항산화 및 면역력 개선용 조성물을 포함하는 것일 수 있다.Food according to another embodiment of the present invention may include the antioxidant and immunity improving composition.
본 발명의 또 다른 일 실시예에 따른 건강기능식품은 상기 항산화 및 면역력 개선용 조성물을 포함하는 것일 수 있다.Health functional food according to another embodiment of the present invention may include the composition for improving the antioxidant and immunity.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 항산화 및 면역력 개선용 조성물은 부리붉은잎 추출물을 포함하는 것일 수 있다.Antioxidant and immune-improving composition according to an embodiment of the present invention may include a beak red leaf extract.
본 명세서에서 사용되는 용어 '추출물'은 상술한 바와 같이 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 식물 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한 외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 식물 추출물에 포함되는 것이다.As used herein, the term 'extract' has a meaning commonly used in the art as a crude extract in the art as described above, but also includes fractions obtained by additional fractionation of the extract in a broad sense. That is, the plant extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods are also included in the plant extract of the present invention.
본 발명에서 이용되는 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The extract used in the present invention may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
본 발명에 사용된 용어 "면역질환"이란 인체 내 면역체계의 과도한 반응으로 일어나는 질환을 뜻하며, 대표적으로 알러지 질환 등이 있다. 그러나 염증 반응이란 결국 생체 내 면역체계의 반응으로 인해 일어나게 되는 것이므로, 염증질환과 면역질환은 크게 볼 때 유사한 범위를 지칭하는 용어로 사용될 수 있는 바, 본 명세서 내에서는 뚜렷하게 구별되는 용어로 사용하지 않고, 혼용하도록 하겠다.As used herein, the term "immune disease" refers to a disease caused by an excessive response of the body's immune system, and representatively includes allergic disease. However, since the inflammatory response eventually occurs due to the response of the immune system in vivo, inflammatory diseases and immune diseases can be used as terms referring to similar ranges in a broad sense, and are not used as distinct terms in this specification. , I will mix it up.
본 발명에 사용된 용어 "염증질환"은 외부물질 또는 내부물질이 유래하는 염증반응으로 인해 일어나는 질환으로 대표적으로 신경염증질환, 관절염 등이 있다.As used herein, the term "inflammatory disease" is a disease caused by an inflammatory reaction derived from an external substance or an internal substance, and includes neuroinflammatory diseases and arthritis.
상기 부리붉은잎 추출물을 포함하는 경우 항산화, 항염 활성과 더불어, 항바이러스 및 항균 효과를 포함하는 면역력을 증진시키는 효과를 낼 수 있다.In the case of containing the red beak leaf extract, it can produce an effect of enhancing immunity, including antiviral and antibacterial effects, in addition to antioxidant and anti-inflammatory activities.
상기 부리붉은잎 추출물을 포함하는 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물은 TNF-α 및 IL-12의 사이토카인 생성을 증가시키는 것일 수 있다.The composition for improving antibacterial, anti-inflammatory, antiviral and immune functions containing the red beak leaf extract may increase cytokine production of TNF-α and IL-12.
사이토카인(cytokine)은 면역세포로부터 분비되는 단백질 면역조절제로서 자가분비형 신호전달(autocrine signaling), 측분비 신호전달(paracrine signaling), 내분비 신호전달(endocrine signaling) 과정에서 특정 수용체와 결합하여 면역반응에 관여한다. 세포의 증식, 분화, 세포사멸 또는 상처 치료 등에 관여하는 다양한 종류의 사이토카인이 존재하며, 특히 면역과 염증에 관여하는 것이 많다.Cytokines are protein immunomodulators secreted from immune cells and bind to specific receptors in the process of autocrine signaling, paracrine signaling, and endocrine signaling to respond to an immune response. get involved in There are various types of cytokines involved in cell proliferation, differentiation, apoptosis, or wound healing, and many of them are particularly involved in immunity and inflammation.
이 중 가장 중요한 면역기능은 인터루킨(Interleukin-1,-6,-12), 인터페론 감마(IFN-γ), 종양괴사인자(TNF)로 알려진 사이토카인의 집단에 의해 수행된다.Among these, the most important immune function is performed by a group of cytokines known as interleukin (Interleukin-1, -6, -12), interferon gamma (IFN-γ), and tumor necrosis factor (TNF).
인터루킨(interleukin, IL)은 백혈구에서 분비되어 면역계 조절 기능에 관여하며 현재 30종류 이상이 알려져 있다. 인터루킨은 면역반응이 일어나는 여러 단계에 작용하여 면역반응을 조절함으로써 인체의 방어작용에 중요한 역할을 하는 물질로, 그 종류는 IL-1,6,12 등이 있다. Interleukin (IL) is secreted from leukocytes and is involved in the immune system regulation function, and more than 30 types are currently known. Interleukin is a substance that plays an important role in the body's defense by controlling the immune response by acting on various stages of the immune response, and its types include IL-1, 6, and 12.
이 중 IL-12는 p35와 p40 단백질로 구성된 사이토카인으로, 선천면역과 획득면역을 서로 연결시키는 매우 중요한 면역학적 기능을 하며, 내인성 항원의 제거에 관여하는 여러 가지 작동세포 즉, 대식세표(macrophage), NK 세포 및 T-세포의 활성화를 유도한다. IL-12의 자극에 의하여 활성화된 NK 세포 및 T-세포는 IFN-γ의 생산을 자극함으로서 초기 선천면역반응을 매개하는 주요 인자로의 특성을 가진다. 또한 T-세포의 면역기구를 주로 Th-1 성향이 되도록 유도하기 때문에 가장 중요한 세포성 면역 매개자이다.Among them, IL-12 is a cytokine composed of p35 and p40 proteins. It plays a very important immunological function by linking innate immunity and acquired immunity, and various effector cells, such as macrophages, involved in the elimination of endogenous antigens. ), induces activation of NK cells and T-cells. NK cells and T-cells activated by stimulation of IL-12 stimulate the production of IFN-γ, and thus have properties as a major factor mediating the initial innate immune response. It is also the most important cellular immune mediator because it induces the immune machinery of T-cells to be mainly Th-1-oriented.
인터페론(interferon, IFN)은 바이러스의 증식 방지나 세포 증식 제어의 기능을 하며 면역 체계에서도 중요한 기능을 한다. 인터페론은 알파(α), 베타(β), 감마(γ), 그리고 오메가(ω)형이 있다. 인터페론-α는 주로 대식세포에 의해 분비되고 인터페론-β는 섬유아세포(fibroblasts)에서 주로 분비된다. 인터페론-γ는 Th1 세포와 NK세포에 의해 분비되고, 인터페론-ω는 영양포 또는 영양아층(Trophoblast)에 의해 주로 분비된다. 특히, 인터페론-γ(IFN-γ)는 T 림프구와 대과립구에서 생산되는 것으로 포식된 미생물이나 항원의 살해를 유도하는 물질이다. 또한, 다양한 면역조절작용을 하며, 대식세포를 활성화시킨다.Interferon (IFN) functions to prevent the proliferation of viruses or control cell proliferation, and also plays an important role in the immune system. There are alpha (α), beta (β), gamma (γ), and omega (ω) types of interferons. Interferon-α is mainly secreted by macrophages, and interferon-β is mainly secreted by fibroblasts. Interferon-γ is secreted by Th1 cells and NK cells, and interferon-ω is mainly secreted by trophoblasts or trophoblasts. In particular, interferon-γ (IFN-γ) is produced by T lymphocytes and macrogranulocytes and is a substance that induces the killing of phagocytic microorganisms or antigens. In addition, it has various immunomodulatory effects and activates macrophages.
종양괴사인자인 TNF(tumor necrosis factor)는 염증반응과 관련된 세포 신호전달 단백질로서, 급성기반응을 유도하는 사이토카인이다. 종양괴사인자는 종양괴사인자-α(TNF-α)와 림포독소(lymphotoxin)라 불리는 종양괴사인자-β(TNF-β)로 나뉘지만, 일반적으로 종양괴사인자는 종양괴사인자-α를 가르킨다.Tumor necrosis factor (TNF) is a cell signaling protein associated with an inflammatory response and is a cytokine that induces an acute phase response. Tumor necrosis factor is divided into tumor necrosis factor-α (TNF-α) and tumor necrosis factor-β (TNF-β) called lymphotoxin, but generally tumor necrosis factor refers to tumor necrosis factor-α .
따라서, 본 발명의 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물에 의한 면역 기능 향상 효과에 경우, 인체 독성과 부작용 문제가 없는 천연물을 사용하여, 면역반응을 활성화시키는 TNF-α 및 IL-12의 사이토카인 생성을 증가시킨다.Therefore, in the case of the immune function improvement effect by the antibacterial, anti-inflammatory, antiviral and immune function improving composition of the present invention, TNF-α and IL-12 that activate the immune response by using natural products that do not have toxicity and side effect problems in the human body. increases cytokine production.
상기 조성물은 알레르기, 염증질환 및 면역질환으로 이루어진 군에서 선택된 질환을 예방하는 것이다.The composition is to prevent a disease selected from the group consisting of allergy, inflammatory disease and immune disease.
알레르기(Allergy)는 대부분의 사람에게서는 특별한 문제가 되지 않는 물질에 대한 면역계의 과민반응에 의해서 나타나는 여러 증상을 일컫는다. 이에는 꽃가루병, 음식 알레르기, 아토피성 피부염, 천식 및 그 외의 과민증 등을 포함하고, 안구 충혈, 가려운 피부 발진, 콧물, 호흡곤란 및 부종 등의 증세를 나타낸다.Allergy refers to various symptoms caused by an overreaction of the immune system to a substance that is not a particular problem for most people. These include hay fever, food allergies, atopic dermatitis, asthma and other anaphylaxis, and show symptoms such as congested eyes, itchy skin rashes, runny nose, difficulty breathing and edema.
염증(inflammation)은 특정 조직의 손상 또는 감염에 대한 일종의 생체 내 반응이며, 주요 매개체는 면역세포로, 조직의 손상된 부위나 감염 부위에 따라 급성 염증(acute inflammation)과 만성 염증(chronic inflammation)으로 나뉜다. 조직의 손상된 부위나 감염 부위가 작거나 일시적 일 때는 급성염증에 의해 해결되지만, 염증 부위가 크거나 만성적 감염 상태일 때는 급성염증에 의해 해결되지 않으며, 만성염증으로 진행된다. 만성염증의 경우는 고질적인 염증성질환으로 진행될 수 있다.Inflammation is a kind of in vivo response to damage or infection in a specific tissue, and the main mediator is immune cells. It is divided into acute inflammation and chronic inflammation depending on the damaged or infected part of the tissue. . When the tissue damage or infection is small or temporary, it is resolved by acute inflammation, but when the inflammation is large or chronically infected, acute inflammation is not resolved and progresses to chronic inflammation. In the case of chronic inflammation, it can progress to a chronic inflammatory disease.
면역질환은 특정 면역 반응이 일어날 경우 문제가 되는 질환을 의미로서, 이에 제한되지는 않으나, 바람직하게는 자가면역질환, 이식거부, 이식편대숙주병 일 수 있으며, 자가면역질환은 크론씨병, 홍반병, 아토피, 류마티스 관절염, 하시모토 갑상선염, 악성빈혈, 에디슨씨 병, 제1형 당뇨, 루프스, 만성피로증후군, 섬유근육통, 갑상선기능저하증과 항진증, 경피증, 베체트병, 염증성 장질환, 다발성 경화증, 중증 근무력증, 메니에르 증후군(Meniere's syndrome), 길리안-바레 증후근(Guilian-Barre syndrome), 쇼그렌 증후군(Sjogren's syndrome), 백반증, 자궁내막증, 건선, 백반증, 전신성 경피증, 천식 또는 궤양성 대장염 등일 수 있다.Immune disease refers to a disease that becomes a problem when a specific immune response occurs, but is not limited thereto, and preferably includes autoimmune disease, transplant rejection, and graft-versus-host disease. Atopy, rheumatoid arthritis, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type 1 diabetes, lupus, chronic fatigue syndrome, fibromyalgia, hypothyroidism and hyperthyroidism, scleroderma, Behcet's disease, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, It may be Meniere's syndrome, Guilian-Barre syndrome, Sjogren's syndrome, vitiligo, endometriosis, psoriasis, vitiligo, systemic scleroderma, asthma or ulcerative colitis.
본원발명의 항산화 및 면역력 개선용 조성물은 부리붉은잎 추출물을 포함하는 것이다.Antioxidant and immune-improving composition of the present invention is to include a beak red leaf extract.
상기 부리붉은잎(Callophyllis rhynchocarpa)은 해조류의 칼리메니아과 지누아리목에 해당하며 몸은 선상의 편평한 막질이며, 촘촘하게 분기하고 부채모양으로 확대하며 높이 5∼7cm, 폭은 하부는 3∼3.5mm 이다. 차상이 점차 다차상 또는 좀 우상과 같은 차장상으로 분기한다. 낭과는 반구상이며 상부의 연변에 가깝게 표면에 생기고 2개의 돌기가 있다. 색은 선홍색이며 질은 막질이고 건조하면 대지에 잘 붙지 않는다.The beak red leaf (Callophyllis rhynchocarpa) corresponds to the algae Callimenia and Chinuari, and the body is a linear flat membrane, densely branched, expanding in a fan shape, 5 to 7 cm in height, and 3 to 3.5 mm in width at the bottom. The second phase gradually diverges into the second phase, such as multi-chasang or small idol. Cystocarp is hemispherical, formed on the surface close to the upper margin, and has two projections. The color is bright red, the quality is membranous, and it does not adhere well to the ground when dry.
주로 일본, 사할린, 오호츠크해, 우리나라 울릉도, 목도, 부산, 완도 등에 분포한다.It is mainly distributed in Japan, Sakhalin, Sea of Okhotsk, and Ulleungdo, Mokdo, Busan, and Wando in Korea.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 발효된 것일 수 있다. 상기 발효된 추출물은 항산화 및 면역 개선효과를 나타내는 유효성분의 활성이 증가되고, 부리붉은잎 특유의 강한 향과 비린 맛을 중화하는 효과를 낼 수 있다.In the composition for improving antioxidant and immunity, the extract may be fermented. The fermented extract increases the activity of active ingredients exhibiting antioxidant and immune-improving effects, and can have the effect of neutralizing the strong aroma and fishy taste unique to red beak leaves.
상기 부리붉은잎 추출물을 포함하는 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 락토바실러스 카제이(Lactobacillus casei); 락토바실러스 람노수스(Lactobacillus rhamnosus); 비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스균; 비피도 박테리움 브레브(Bifidobacterium breve) 비피더스균; 락토바실러스 아시도 필루스(Lactobacillus acidophilus); 바실러스 서브틸리스(Bacillus subtilis) 및 이들의 혼합물로 이루어진 군에서 선택되는 어느 하나가 접종되어 발효된 것일 수 있다.In the antioxidant and immune-improving composition comprising the beak red leaf extract, the extract is Lactobacillus casei; Lactobacillus rhamnosus; Bifidobacterium bifidum Bifidobacteria; Bifidobacterium breve Bifidobacteria; Lactobacillus acidophilus; Any one selected from the group consisting of Bacillus subtilis and mixtures thereof may be inoculated and fermented.
바람직하게 상기 추출물은 락토바실러스 카제이(Lactobacillus casei) 및 비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스 균이 접종되어 발효된 것일 수 있다. 상기 미생물에 의한 발효를 진행하는 경우 항산화 활성을 높이고 면역력 개선효과를 높이면서도, 부리붉은잎 특유의 향미를 개선하는 효과를 낼 수 있다.Preferably, the extract may be inoculated with and fermented by Lactobacillus casei and Bifidobacterium bifidum. In the case of fermentation by the microorganism, it is possible to increase the antioxidant activity and improve the immunity improvement effect, while improving the unique flavor of the red leaf.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 물, 탄소수 1 내지 6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 어느 하나를 추출 용매로 하여 추출된 것일 수 있다.In the antioxidant and immunity-improving composition, the extract may be extracted by using any one selected from the group consisting of water, lower alcohols having 1 to 6 carbon atoms, and mixtures thereof as an extraction solvent.
상기 추출물은 상기 부리붉은잎을 분쇄한 분쇄물에 대하여 물, 에탄올, 메탄올 등과 같은 탄소수 1 내지 10 알코올과 같은 극성 용매 또는 알코올과 물의 1:0.1 내지 1:10의 혼합비를 갖는 혼합 용매를 사용하여 용출할 수 있으며, 보다 상세하게는 추출 용매로 물을 이용할 수 있다. 이때, 추출 온도는 10℃ 내지 100℃, 바람직하게는 실온에서 추출한 추출물일 수 있다.The extract is obtained by using a polar solvent such as alcohol having 1 to 10 carbon atoms such as water, ethanol, methanol, etc. or a mixed solvent having a mixing ratio of 1:0.1 to 1:10 of alcohol and water with respect to the pulverized product of the red leaf. It can be eluted, and more specifically, water can be used as an extraction solvent. At this time, the extraction temperature may be 10 ℃ to 100 ℃, preferably the extract extracted at room temperature.
상기 추출 용매는 시료의 중량 기준으로 2 내지 50배를 사용할 수 있으며, 바람직하게는 2 내지 20배이다. 추출을 위해 시료는 추출 용매에서 침출을 위해 1 내지 72 시간 동안 방치될 수 있으며, 상세하게는 1 내지 24시간 동안 방치될 수 있다. 또한 추출 후 여과된 것일 수 있다.The extraction solvent may be used in an amount of 2 to 50 times, preferably 2 to 20 times, based on the weight of the sample. For extraction, the sample may be left for leaching in the extraction solvent for 1 to 72 hours, specifically 1 to 24 hours. It may also be filtered after extraction.
여과된 추출물을 진공 회전 농축기로 감압 농축하여 수득한 결과물일 수 있으나, 이에 제한되지 않고, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이의 조정제물 또는 정제물을 모두 포함한다.It may be a product obtained by concentrating the filtered extract under reduced pressure with a vacuum rotary evaporator, but is not limited thereto, and includes all extracts, diluted or concentrated solutions of extracts, dried products obtained by drying extracts, and crude or purified products thereof.
상기 항산화 및 면역력 개선용 조성물에 있어서, 상기 추출물은 세모가사리 추출물, 대황(Eisenia bicyclis) 추출물, 쇠서나물 추출물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 더 포함하는 것일 수 있다.In the antioxidant and immunity-improving composition, the extract may further include any one selected from the group consisting of semogasari extract, rhubarb (Eisenia bicyclis) extract, horse chestnut extract, and mixtures thereof.
바람직하게 상기 부리붉은잎 추출물 100 중량부에 대하여 세모가사리 추출물을 1 내지 10 중량부, 대황(Eisenia bicyclis) 추출물 1 내지 10 중량부, 쇠서나물 추출물 10 내지 20중량부로 더 포함하는 것일 수 있다. 상기 범위에 의하는 경우 항산화 활성 및 면역력 개선 효과가 더 높아질 수 있다.Preferably, it may further include 1 to 10 parts by weight of semogasari extract, 1 to 10 parts by weight of rhubarb (Eisenia bicyclis) extract, and 10 to 20 parts by weight of horse chestnut extract based on 100 parts by weight of the red leaf extract. In the case of the above range, the antioxidant activity and immunity improvement effect may be higher.
바람직하게 상기 추출물은 발효된 것이고, 쌀뜨물 및 당밀의 혼합물을 더 포함하는 것일 수 있다. 쌀뜨물 및 당밀의 혼합물이 포함되면 상기 항산화 활성 및 면역활성을 배시키면서도 부리붉은잎 특유의 강하거나 비린 향을 제거하여 기호성이 높은 식품을 제공하게 할 수 있다. Preferably, the extract is fermented, and may further include a mixture of rice water and molasses. When the mixture of rice water and molasses is included, it is possible to provide food with high palatability by removing the strong or fishy scent peculiar to the red beak leaf while doubling the antioxidant activity and immune activity.
상기 쌀뜨물 및 당밀의 혼합물은 쌀뜨물 100 중량부에 대하여 당밀 1 내지 10 중량부가 혼합된 것이고, 상기 혼합물은 상기 부리붉은잎 추출물 100 중량부에 대하여 50 내지 200 중량부로 포함되는 것일 수 있다. 상기 범위에 의하는 경우 상승효과 및 기호성을 향상시키는 효과를 낼 수 있다.The mixture of rice water and molasses is a mixture of 1 to 10 parts by weight of molasses based on 100 parts by weight of rice water, and the mixture may be included in 50 to 200 parts by weight based on 100 parts by weight of the red leaf extract. In the case of the above range, a synergistic effect and an effect of improving palatability can be produced.
상기 쌀뜨물은 쌀 또는 쌀겨를 세척하는 과정에서 수득할 수 있다.The rice water can be obtained in the process of washing rice or rice bran.
본 발명의 다른 일 실시예에 따른 식품은 상기 항산화 및 면역력 개선용 조성물을 포함하는 것일 수 있다.Food according to another embodiment of the present invention may include the antioxidant and immunity improving composition.
본 발명의 또 다른 일 실시예에 따른 건강기능식품은 상기 항산화 및 면역력 개선용 조성물을 포함하는 것일 수 있다.Health functional food according to another embodiment of the present invention may include the composition for improving the antioxidant and immunity.
구체적인 예로, 상기 식품 조성물을 이용하여 항균, 항염, 항바이러스 및 면역 기능 개선 효과를 증강시킬 수 있는 가공식품을 제조할 수 있다. 이런 가공식품에는 예를 들어, 과자, 차, 음료, 주류, 발효식품, 통조림, 우유가공식품, 육류가공식품, 국수 등을 포함한다. 과자는 비스킷, 파이, 케익, 빵, 캔디, 젤리, 껌, 시리얼등을 포함한다. 음료는 음용수, 탄산음료, 기능성 이온음료, 기능성이온음료, 주스(예를들어, 사과, 배, 포도, 알로에, 감귤, 복숭아, 당근, 토마토 쥬스 등), 식혜 등을 포함한다. 주류는 청주, 위스키, 소주, 맥주, 양주, 과실주 등을 포함한다. 발효식품은 간장, 된장, 고추장 등을 포함한다. 통조림은 수산물 통조림(예들 들어, 참치, 고등어, 꽁치, 소라 통조림 등), 축산물 통조림(쇠고기, 돼지고기, 닭고기, 칠면조 통조림 등), 농산물 통조림(옥수수, 복숭아, 파일애플 통조림 등)을 포함한다. 우유가공식품은 치즈, 버터, 요구르트 등을 포함한다. 육류가공식품은 돈까스, 비프까스, 치킨까스, 소세지. 탕수육, 너겟류, 너비아니 등을 포함한다. 밀봉포장생면 등의 국수를 포함한다. 이 외에도 상기 조성물은 레토르트식품, 스프류 등에 사용될 수 있다.As a specific example, a processed food capable of enhancing antibacterial, anti-inflammatory, antiviral and immune function improving effects can be prepared using the food composition. Such processed foods include, for example, sweets, tea, beverages, alcoholic beverages, fermented foods, canned foods, processed milk products, processed meat products, noodles, and the like. Sweets include biscuits, pies, cakes, breads, candies, jellies, chewing gum, cereals, and the like. Beverages include drinking water, carbonated beverages, functional ionic beverages, functional ionic beverages, juice (eg, apple, pear, grape, aloe, tangerine, peach, carrot, tomato juice, etc.), sikhye, and the like. Liquor includes rice wine, whiskey, soju, beer, liquor, fruit wine, and the like. Fermented foods include soy sauce, soybean paste, red pepper paste, and the like. Canned food includes canned seafood (e.g., canned tuna, mackerel, saury, canned conch, etc.), canned livestock products (canned beef, pork, chicken, turkey, etc.), canned agricultural products (canned corn, peaches, canned pineapple, etc.). Milk processed foods include cheese, butter, yogurt, and the like. Processed meat products include pork cutlet, beef cutlet, chicken cutlet, and sausage. Includes sweet and sour pork, nuggets, nubani, etc. It includes noodles such as sealed packaged raw noodles. In addition to this, the composition can be used for retort food, soup, and the like.
본 발명의 다른 일 실시예에 따른 식품 조성물은 상기 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물을 유효성분으로 포함하여 제조한 것이다.A food composition according to another embodiment of the present invention is prepared by including the antibacterial, anti-inflammatory, antiviral and immune function improving composition as an active ingredient.
본 발명의 다른 일 실시예에 따른 건강기능식품은 상기 부리붉은잎을 포함하는 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물을 포함하는 것일 수 있다.Health functional food according to another embodiment of the present invention may include a composition for antibacterial, anti-inflammatory, antiviral and immune function improvement including the red beak leaf.
상기 건강기능식품은 항균, 항염, 항바이러스 및 면역활성을 개선하기 위하여 섭취할 수 있는 것이면 특별히 제한되지 않는다.The health functional food is not particularly limited as long as it can be ingested to improve antibacterial, anti-inflammatory, antiviral and immune activity.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods. Active ingredients can be appropriately used depending on their purpose of use (prevention or improvement). In general, when preparing food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은There is no particular limitation on the type of health functional food. The health functional food composition of the present invention can be made into food, particularly functional food. The functional food of the present invention
식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.It includes components commonly added during food preparation, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink, natural carbohydrates or flavors may be included as additional ingredients in addition to active ingredients. The natural carbohydrates are monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrins, cyclodextrins, etc.) or sugar alcohols (eg, maltose, sucrose, etc.) , xylitol, sorbitol, erythritol, etc.) are preferred. As the flavoring agent, natural flavoring agents (eg, thaumatin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used.
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다.In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonic acid It may further contain a carbonation agent used in beverages and the like.
본 발명은 부리붉은잎 추출물 또는 발효된 부리붉은잎 추출물을 유효성분으로 하면서 세포독성 등의 부작용의 문제가 없으면서도 장기간 복용할 수 있는 기능성 조성물을 제공한다.The present invention provides a functional composition that can be taken for a long period of time without side effects such as cytotoxicity while using the fermented red leaf extract or fermented red leaf extract as an active ingredient.
본 발명은 항산화 및 면역력 증가 효과를 나타낼 수 있는 기능성 조성물을 제공한다.The present invention provides a functional composition capable of exhibiting antioxidant and immune-enhancing effects.
본 발명은 향미와 기호성이 우수하여 대중화가 용이한 부리붉은잎 기반의 기능성 식품 또는 건강기능식품을 제공한다.The present invention provides a red leaf-based functional food or health functional food that is easy to popularize due to its excellent flavor and palatability.
도 1은 본 발명의 일 실시예 따른 항산화 활성의 평가결과에 관한 것이다.
도 2는 본 발명의 일 실시예에 따른 조성물로 처리된 배양액 내에 존재하는 산화질소 농도를 측정한 그래프이다.
도 3은 본 발명의 일 실시예에 따른 조성물로 처리된 배양액 내에 존재하는 TNF-α 농도를 측정한 그래프이다.
도 4은 본 발명의 일 실시예에 따른 조성물로 배양액 내에 존재하는 인터루킨-12 농도를 측정한 그래프이다.1 relates to evaluation results of antioxidant activity according to an embodiment of the present invention.
Figure 2 is a graph measuring the concentration of nitric oxide present in the culture medium treated with the composition according to an embodiment of the present invention.
Figure 3 is a graph measuring the concentration of TNF-α present in the culture medium treated with the composition according to an embodiment of the present invention.
Figure 4 is a graph measuring the concentration of interleukin-12 present in the culture medium with the composition according to an embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.
[제조예: 추출물의 제조][Preparation Example: Preparation of extract]
1. 부리붉은잎 추출물의 제조1. Preparation of red beak leaf extract
세척 및 건조된 부리붉은잎을 분쇄하고, 열수로 가압추출한 뒤, 농축 및 여과하여 부리붉은잎 추출물(P1)을 제조하였다.The washed and dried red leaves were pulverized, extracted under pressure with hot water, concentrated and filtered to prepare a red leaf extract (P1).
2. 기타 추출물의 제조2. Preparation of other extracts
상기 부리붉은잎 추출물과 동일한 방법으로 세모가사리 추출물(R1), 대황(Eisenia bicyclis) 추출물(R2), 및 쇠서나물 추출물(R3)을 제조하였다.Semogasari extract (R1), rhubarb (Eisenia bicyclis) extract (R2), and horse chestnut extract (R3) were prepared in the same manner as the red beak leaf extract.
3. 혼합 추출물 및 발효 추출물의 제조3. Preparation of mixed extract and fermented extract
혼합에 의한 상승효과를 확인하기 위하여 하기의 [표 1]과 같은 조성에 따라 혼합 추출물을 제조하였다.In order to confirm the synergistic effect by mixing, a mixed extract was prepared according to the composition shown in [Table 1] below.
(단위: 중량부)(unit: parts by weight)
4. 발효 추출물의 제조4. Preparation of fermented extract
추출물 발효에 의한 상승효과를 확인하기 위하여 하기의 [표 2]에 대한 발효를 진행하였다. 발효(S)균주로 S1(락토바실러스 카제이(Lactobacillus casei)), S2(비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스 균), 및 S3(S1과 S2의 혼합)을 접종하면서 상승효과를 확인하였다. 한편 쌀뜨물 및 당밀의 혼합물(U)는 쌀뜨물 100 중량부에 대하여 당밀을 2 중량부로 혼합하였다.In order to confirm the synergistic effect by fermentation of the extract, fermentation was performed according to [Table 2] below. Synergistic effect while inoculating S1 (Lactobacillus casei), S2 (Bifidobacterium bifidum bifidus bacteria), and S3 (mixture of S1 and S2) as fermentation (S) strains Confirmed. On the other hand, the mixture (U) of rice water and molasses was mixed with 2 parts by weight of molasses based on 100 parts by weight of rice water.
(단위: 중량부)(unit: parts by weight)
[실험예: 항산화 및 면역력 증강 효과][Experimental Example: Antioxidant and immune enhancing effect]
1. 항산화 활성 평가1. Evaluation of antioxidant activity
각 제조예에 따른 추출물의 항산화 활성을 평가하기 위하여 DPPH 라디칼 소거능 실험(DPPH radical scavenging activity)을 진행하였다. DPPH radical 소거활성은 Yamaguchi 등의 방법에 의하여 측정하였다. 60 ㎕ 시료 용액에 60 ㎕ DPPH 용액(60 μM)을 첨가하여 10초 동안 교반한 다음, 혼합용액을 quartz capillary tube에 옮겨 2분 후에 ESR로 측정하였다.In order to evaluate the antioxidant activity of the extract according to each preparation example, a DPPH radical scavenging activity test was conducted. DPPH radical scavenging activity was measured by the method of Yamaguchi et al. 60 μl DPPH solution (60 μM) was added to the 60 μl sample solution, stirred for 10 seconds, and then the mixed solution was transferred to a quartz capillary tube and measured by ESR after 2 minutes.
그 결과를 하기의 [도 1]에 나타내었다.The results are shown in [Figure 1] below.
하기의 [도 1]을 참조하면 본 발명에 따른 제조예에서 항산화 활성을 확인할 수 있으며, 특히 M3 내지 M4의 조합범위에서 상승효과가 나타나는 점을 확인할 수 있다. 또한 발효에 의하는 B3 및 B4의 경우 추가적인 상승효과를 나타내는 점을 확인할 수 있다. 특히 B4의 항산화 활성이 가장 우수하다는 점을 확인할 수 있다.Referring to the following [Figure 1], it can be confirmed that the antioxidant activity in the production example according to the present invention, in particular, it can be confirmed that the synergistic effect appears in the combination range of M3 to M4. In addition, it can be confirmed that B3 and B4 by fermentation show an additional synergistic effect. In particular, it can be confirmed that the antioxidant activity of B4 is the most excellent.
2. 산화질소생성량 측정2. Measurement of nitric oxide production
상기 제조예에 따른 조성물이 면역활성이 미치는 능력을 확인하기 위하여 griess reagent[1% (w/v) sulfanilamide in 5%(v/v) 인산(phosphoric acid)과 0.1% (w/v) 나프틸에틸렌다이아민-염산(naphtylethylenediamine-HCl)]을 이용하여 세포배양액 중에 존재하는 NO2-의 생성농도를 측정하였다. 구체적으로 RAW 264.7 세포를 6-well plate에 5X105 cell/well의 농도로 분주하여 24시간 배양한 후에 각 제조된 시료를 각각 처리하였으며, 정상 대조군으로 상기 시료를 0ug/mL로 처리하고, 양성 대조군으로 지방질 다당류를 1ug/mL로 처리하여 24시간 동안 배양하였다. 세포 배양액의 상층액과 동량의 griess reagent를 혼합하여 상온에서 15분 반응시킨 후 540 nm에서 흡광도를 측정하였으며, 아질산소듐(sodium nitrite)을 이용하여 작성한 표준곡선으로부터 산화질소 농도를 구하여 환산하였다.In order to confirm the ability of the composition according to the preparation example to have an immune activity, griess reagent [1% (w / v) sulfanilamide in 5% (v / v) phosphoric acid (phosphoric acid) and 0.1% (w / v) naphthyl Ethylenediamine-hydrochloric acid (naphtylethylenediamine-HCl)] was used to measure the production concentration of NO 2- present in the cell culture medium. Specifically, RAW 264.7 cells were dispensed in a 6-well plate at a concentration of 5X10 5 cell/well, cultured for 24 hours, and then each prepared sample was treated. As a normal control, the sample was treated with 0ug/mL, and a positive control The lipopolysaccharide was treated with 1ug/mL and cultured for 24 hours. After mixing the supernatant of the cell culture medium and the same amount of griess reagent and reacting at room temperature for 15 minutes, the absorbance was measured at 540 nm, and the nitric oxide concentration was obtained and converted from a standard curve prepared using sodium nitrite.
그 결과를 하기의 [도 2]에 나타내었다.The results are shown in [Figure 2] below.
산화질소의 생성은 면역계에서 종양세포나 세포내 감염된 미생물에 대한 방어 작용을 하는 중요한 신호전달 물질로 알려져 있는데, 하기의 [도 2]를 참조하면, 제조예 전반에 있어서 일정한 산화질소 생성에 대한 억제 활성이 나타나는 것을 확인할 수 있었으며, 실시예 전체에 걸쳐 양성대조군에 비하여 40% 미만의 산화질소를 생성하는 것을 확인하였다.The production of nitric oxide is known as an important signaling substance that acts as a defense against tumor cells or intracellularly infected microorganisms in the immune system. It was confirmed that the activity appeared, and it was confirmed that less than 40% of nitric oxide was produced compared to the positive control group throughout the examples.
특히 M3 및 M4의 조합범위에서 상승효과가 나타나는 점을 확인할 수 있었으며, 발효에 의하는 B3 및 B4의 경우 추가적인 상승효과를 나타내는 점을 확인할 수 있다. 특히 B4의 산화질소 생성을 억제하는 활성이 가장 우수하다는 점을 확인할 수 있다. 상기 산화질소의 과량 생성은 전신적 염증을 유발하여 생체에 여러 부정적인 영향을 미치지만 적정량의 산화질소의 생성은 선천성 면역의 중요한 인자로써 여겨지므로 상기 조성물에 의하는 경우 우수한 면역활성을 나타낼 수 있다.In particular, it was confirmed that a synergistic effect appeared in the range of combinations of M3 and M4, and it was confirmed that an additional synergistic effect was exhibited in the case of B3 and B4 by fermentation. In particular, it can be confirmed that the activity of suppressing the production of nitric oxide of B4 is the most excellent. Excessive production of nitric oxide causes systemic inflammation and has various negative effects on the living body, but production of an appropriate amount of nitric oxide is considered an important factor in innate immunity, so the composition can exhibit excellent immune activity.
3. TNF-α 및 IL-12 생성능 측정3. Measurement of TNF-α and IL-12 production ability
세포배양액 내의 TNF-α 및 IL-12의 분비량은 ELISA를 이용하여 측정하였다. 96-well plate에 capture antibody(anti-mouse TNF-α 및 IL-12)를 각각 분주하여 4 ℃에서 코팅시켰다. 이를 washing buffer(0.05% Tween-20이 포함된 PBS)로 세척한 후 10% FBS가 함유된 phosphate-buffered saline(PBS)으로 1시간 동안 blocking 한 뒤 washing buffer로 세척하였다. 각 microplate 에는 산화질소를 측정하였던 것과 동일한 세포배양액의 상층액을 100 uL씩 분주하여 실온에서 2시간 반응시킨 후 washing buffer로 세척하였다. 희석한 각각의 biotinylated anti-mouse TNF-α 및 인터루킨-6 detection antibody와 streptavidin-horseradish peroxidase conjugate 용액을 넣고 실온에서 1시간 반응시켰다. 반응시킨 plate를 washing buffer로 세척한 후 tetramethylbenzidine(TMB) substrate solution을 첨가하여 암실에서 30분 동안 발색시킨 다음 1 M 인산을 첨가하여 발색반응을 정지시키고 450 nm에서 흡광도를 측정하였다.The secretion of TNF-α and IL-12 in the cell culture medium was measured using ELISA. Capture antibodies (anti-mouse TNF-α and IL-12) were each dispensed on a 96-well plate and coated at 4 °C. It was washed with washing buffer (PBS containing 0.05% Tween-20), blocked with phosphate-buffered saline (PBS) containing 10% FBS for 1 hour, and then washed with washing buffer. Each microplate was dispensed with 100 uL of the supernatant of the same cell culture as in which nitric oxide was measured, reacted at room temperature for 2 hours, and washed with washing buffer. Each diluted biotinylated anti-mouse TNF-α and interleukin-6 detection antibody and streptavidin-horseradish peroxidase conjugate solution were added and reacted at room temperature for 1 hour. After washing the reacted plate with washing buffer, tetramethylbenzidine (TMB) substrate solution was added to develop color in a dark room for 30 minutes, and 1 M phosphoric acid was added to stop the color reaction, and absorbance was measured at 450 nm.
그 결과를 하기 [도 3]에 나타내었다. 하기의 [도 3]을 참조하면, 염증성 사이토카인인 TNF-α 생성능에 대한 면역활성을 검토한 결과, M3 및 M4에 의하는 경우 큰포식세포(macrophage) 자극에 의한 TNF-α의 분비를 증가시키는 것을 확인하였다. 또한, B1 내지 B4에 의하는 경우 양성 대조군(지방질 다당류)이 생성한 TNF-α 분비 보다 촉진된다는 사실을 확인할 수 있다.The results are shown in [Figure 3] below. Referring to [Figure 3] below, as a result of examining the immune activity for the ability to produce TNF-α, an inflammatory cytokine, in the case of M3 and M4, secretion of TNF-α by macrophage stimulation is increased confirmed to do so. In addition, it can be confirmed that in the case of B1 to B4, the secretion of TNF-α produced by the positive control group (lipopolysaccharide) is promoted more.
또한, [도 4]을 참조하면 M3 및 M4에서 면역매개인자인 IL-12의 생성을 농도 의존적으로 증가한다는 점을 확인할 수 있었다. 또한 발효조성물로서 B3 및 B4에 의하는 경우 IL-12의 생성이 보다 촉진되는 점을 알 수 있다. 이는 상기 조성물에 의하는 경우 인터루킨-6의 생성량을 증가시켜 B림프구를 분화시킴으로써 면역반응에 중요한 역할을 할 수 있다는 것으로 이해할 수 있다.In addition, referring to [Figure 4], it was confirmed that the production of IL-12, an immune mediator, increased in a concentration-dependent manner in M3 and M4. In addition, it can be seen that the production of IL-12 is more promoted when B3 and B4 are used as fermented compositions. It can be understood that the above composition can play an important role in the immune response by increasing the production of interleukin-6 and differentiating B lymphocytes.
4. 기호성 평가4. Evaluation of palatability
해초류의 강한 향과 맛에 대한 거부감을 가진다고 응답한 성인을 피시험자로 10인을 선정하였고, 상기 제조예에 따른 추출물을 차음료로 제공한 뒤 향미와 맛을 포함한 종합기호도를 평가하도록 하였다. 종합기호도는 1 내지 10의 지수로 평가하였으며, 상기 지수는 그 숫자가 높을수록 기호도가 우수한 것이다.Ten adults who responded that they had a strong sense of aversion to the strong scent and taste of seaweeds were selected as test subjects, and the extract according to the preparation example was provided as a tea drink, and then the overall acceptability including flavor and taste was evaluated. The overall acceptability was evaluated with an index of 1 to 10, and the higher the index, the better the acceptability.
그 결과를 하기의 [표 3]에 나타내었다.The results are shown in [Table 3] below.
(단위: 지수)(Unit: index)
상기 [표 3]을 참조하면, 본 발명의 실시예에 의하는 경우 부리붉은잎의 강하고 비린 향에 거부감을 가지는 소비자에게는 기호성이 낮은 것으로 평가되었지만, 일정한 범위에서 발효된 B3의 경우 비린 향이 다소 중화되는 것을 확인할 수 있었다. 특히 발효 조성물 중 쌀뜨물 및 당밀의 혼합물이 첨가된 B4 의 경우 향미와 맛이 상당 부분이 개선되는 점을 확인할 수 있다.Referring to [Table 3], in the case of the embodiment of the present invention, the palatability was evaluated to be low for consumers who have a reluctance to the strong and fishy scent of red leaves, but in the case of B3 fermented in a certain range, the fishy scent is somewhat neutralized was able to confirm that In particular, in the case of B4 to which a mixture of rice water and molasses was added in the fermented composition, a significant portion of flavor and taste was improved.
따라서 상기 범위에 의하는 경우 부리붉은잎을 이용하면서도 기호성이 높은 항산화 및 면역기능 개선용 기능성 식품 또는 건강기능식품으로서 그 보급을 보다 용이하게 할 수 있다는 점을 확인할 수 있다.Therefore, in the case of using the above range, it can be confirmed that it can be more easily supplied as a functional food or health functional food for improving antioxidant and immune function with high palatability while using red leaves.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also made according to the present invention. falls within the scope of the rights of
Claims (7)
세모가사리 추출물, 대황(Eisenia bicyclis) 추출물 및 쇠서나물 추출물을 더 포함하며,
상기 부리붉은잎 추출물 100 중량부에 대하여 세모가사리 추출물 1 내지 10 중량부, 대황(Eisenia bicyclis) 추출물 1 내지 10 중량부 및 쇠서나물 추출물 10 내지 20 중량부로 포함하는
항산화 및 면역력 개선용 조성물. Contains red leaf extract,
Further comprising semogasari extract, rhubarb (Eisenia bicyclis) extract and horse chestnut extract,
1 to 10 parts by weight of semogasari extract, 1 to 10 parts by weight of rhubarb (Eisenia bicyclis) extract, and 10 to 20 parts by weight of horse chestnut extract, based on 100 parts by weight of the red leaf extract.
A composition for antioxidant and immunity improvement.
상기 추출물은 발효된 것인
항산화 및 면역력 개선용 조성물.According to claim 1,
The extract is fermented
A composition for antioxidant and immunity improvement.
상기 추출물은 락토바실러스 카제이(Lactobacillus casei); 락토바실러스 람노수스(Lactobacillus rhamnosus); 비피도 박테리윰 비피듐(Bifidobacterium bifidum) 비피더스균; 비피도 박테리움 브레브(Bifidobacterium breve) 비피더스균; 락토바실러스 아시도 필루스(Lactobacillus acidophilus); 바실러스 서브틸리스(Bacillus subtilis) 및 이들의 혼합물로 이루어진 군에서 선택되는 어느 하나가 접종되어 발효된 것인
항산화 및 면역력 개선용 조성물.According to claim 1,
The extract is Lactobacillus casei; Lactobacillus rhamnosus; Bifidobacterium bifidum Bifidobacteria; Bifidobacterium breve Bifidobacteria; Lactobacillus acidophilus; Any one selected from the group consisting of Bacillus subtilis and mixtures thereof is inoculated and fermented
A composition for antioxidant and immunity improvement.
상기 추출물은 물, 탄소수 1 내지 6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 어느 하나를 추출 용매로 하여 추출된 것인
항산화 및 면역력 개선용 조성물.According to claim 1,
The extract is extracted by using any one selected from the group consisting of water, lower alcohols having 1 to 6 carbon atoms, and mixtures thereof as an extraction solvent.
A composition for antioxidant and immunity improvement.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200128712A KR102534513B1 (en) | 2020-10-06 | 2020-10-06 | Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200128712A KR102534513B1 (en) | 2020-10-06 | 2020-10-06 | Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220046032A KR20220046032A (en) | 2022-04-14 |
KR102534513B1 true KR102534513B1 (en) | 2023-05-19 |
Family
ID=81211315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200128712A KR102534513B1 (en) | 2020-10-06 | 2020-10-06 | Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102534513B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102674571B1 (en) | 2024-03-08 | 2024-06-11 | 김혜빈 | Antioxidant cosmetic composition containing buckwheat honey |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101856693B1 (en) * | 2017-09-13 | 2018-05-14 | (주)바이오션 | Method for preparing fermented mixture comprising Laminaria japonica, Undaria pinnatifida Suringer and hizikia fusiforme and composition for enhancing antioxidant activity and immune activity comprising fermented mixture prepared thereby |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070089288A (en) | 2006-02-28 | 2007-08-31 | 인제대학교 산학협력단 | Composition comprising an extract of ammomum xanthioides wallich showing antioxidative effect |
KR101734979B1 (en) | 2014-07-21 | 2017-05-12 | 셀루스원 주식회사 | Composition for preventing and treating cancer, and enhancing the immune action |
-
2020
- 2020-10-06 KR KR1020200128712A patent/KR102534513B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101856693B1 (en) * | 2017-09-13 | 2018-05-14 | (주)바이오션 | Method for preparing fermented mixture comprising Laminaria japonica, Undaria pinnatifida Suringer and hizikia fusiforme and composition for enhancing antioxidant activity and immune activity comprising fermented mixture prepared thereby |
Non-Patent Citations (2)
Title |
---|
Ahn et al., Ethanol extract of Callophyllis japonica enhances nitric oxide and tumor necrosis factor-alpha production in mouse macrophage cell line, RAW 264.7 cells. Oriental Pharmacy and Experimental Medicine. Vol. 7, No. 4, pp. 341-347(2007) 1부.* |
Kang et al., Antioxidant Activity of Ethanol Extract of Callophyllis japonica. PHYTOTHERAPY RESEARCH. Vol. 19, pp. 506-510 (2005) 1부.* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102674571B1 (en) | 2024-03-08 | 2024-06-11 | 김혜빈 | Antioxidant cosmetic composition containing buckwheat honey |
Also Published As
Publication number | Publication date |
---|---|
KR20220046032A (en) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102513040B1 (en) | Composition for antioxidant and immunity improvement activity containing natural extracts and health functional food containing the same | |
KR101585159B1 (en) | a composition comprising an extract of fermented Sword Bean as an active ingredient for preventing or treating inflammation, or allergy | |
KR101705548B1 (en) | Composition for enhancing immune response comprising extract of Apios americana Medikus or fermented extract of the same | |
KR102127911B1 (en) | The composition of fermented beverage for immunity enhancement and method for production thereof | |
JP2020524711A (en) | Inactivated Bacillus coagulans and its use for improving physical performance | |
KR101484021B1 (en) | A Composition Comprising the extract of combined herbs including Curcuma Longa L. for immuno-stimulating activity | |
JP2003135028A (en) | Functional food for health | |
KR102534513B1 (en) | Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same | |
KR102424477B1 (en) | Functional composition containing seaweed and health functional food containing same | |
KR102424474B1 (en) | Method of manufacturing a functional composition comprising seaweed | |
KR102315959B1 (en) | A composition for reinforcing immune function comprising the extract of oat sprout | |
KR102461788B1 (en) | Composition for enhancing immunity comprising NueDongChungHaCho(Paecilomyces tenuipes) water extract | |
KR101862282B1 (en) | A Composition Comprising the combined herbal extract of Dendropanax morbifera and Acanthopanax senticosus HARMS for immuno-stimulating activity | |
KR102326439B1 (en) | Antimicrobial, anti-inflammatory, antiviral and immunologically enhancing composition comprising ginseng | |
KR20210085627A (en) | Composition for Enhancing Immunity Comprising Complex Extracts of Gryllus bimaculatus and Tenebrio molitor Linnaues as Active Ingredient | |
KR101832357B1 (en) | A composition for the enhancement of immune system comprising extracts of soybean sprouts as an active ingredient and the method of preparation thereof | |
KR102527252B1 (en) | A composition for improving immune comprising enzyme hydrolysate containing Rhodiola sachalinensis A. Bor | |
KR20150051174A (en) | Composition for immune enhancement comprising ethanol extract of Ulmus cortex | |
KR20200082426A (en) | Vegetable soup composition comprising beta-glucan for enhancing function of immunity and method thereof | |
KR102093817B1 (en) | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same | |
KR101894657B1 (en) | A composition comprising mixture of the extract of Broadleaf Liriope and silkworm powder for improving immunity | |
KR20180050634A (en) | Composition for immune enhancement comprising ethanol extract of Ulmus cortex | |
KR102499700B1 (en) | Functional composition comprising lactic acid bacteria, propolis, vitamins and collagen | |
KR102602070B1 (en) | A composition for improving intestinal health comprising Salicornia herbacea mixed fermentation product | |
KR102176839B1 (en) | Composition for enhancing immunity comprising extracts of Deer Velvet and Eleutherococcus senticosus and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |